Ardent phase 2b clinical trial of IMR-687 : Imara wraps up patient enrollment
Imara Inc. said that it has wrapped up enrollment of patients in the Ardent phase 2b clinical trial of IMR-687 (tovinontrine) for sickle cell disease. According to the US-based clinical-stage biopharma company, IMR-687 is a potent small molecule inhibitor of PDE9. Rahul Ballal — President and CEO of Imara, commenting on the Ardent phase 2b […]